Sun Pharma Share Price Down by 1.78%; Gross Sales Rise 10.5% in Q2 FY 2025 Earnings

Sun Pharmaceutical Industries Limited announced its financials for the second quarter ending September 30, 2024. 

Q2 FY 2025 Financial Highlights

The company achieved gross sales of ₹1,32,642 million, marking a 10.5% increase compared to the same period last year. Notably, India formulation sales reached ₹42,652 million, up 11%, while US formulation sales saw a remarkable 20.3% growth, totalling US$517 million.

In terms of profitability, Sun Pharma reported an EBITDA of ₹39,390 million, which includes other operating revenues, demonstrating a 23.9% increase year-over-year. This growth resulted in a healthy EBITDA margin of 29.6%. The net profit for Q2 FY25 also showcased a rise of 28%, amounting to ₹30,402 million.

In addition to its strong sales and profit figures, Sun Pharma’s external sales of Active Pharmaceutical Ingredients (API) reached ₹5,338 million in Q2 FY25, representing a 7.4% growth over the previous year. 

H1 FY 2025 Financial Highlights

For the first half of FY25, Sun Pharma continued its strong performance, with gross sales of ₹257,887 million, reflecting an 8.4% growth. India formulation sales were ₹84,097 million, up 13.6%, while US formulation sales totalled US$983 million, increasing by 9.1%. The company’s EBITDA for H1 FY25 was ₹75,466 million, an increase of 15.9%, leading to an EBITDA margin of 29.1%. The net profit for the first half stood at ₹58,758 million, a 24.5% increase over the adjusted net profit for H1 FY24.

On October 29, 2024, Sun Pharma share price opened at ₹1,922.00, up from its previous close of ₹1,902.90. At 11:30 AM, the share price of Sun Pharma was trading at ₹1,869.00, down by 1.78%.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.